7 terminated. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 7 |
| Phase 1 | 1 | Terminated 1 |
Follow Adrenal Cortex Diseases: new trials by email Literature Review of Adrenal Cortex Diseases trials Research Report on Adrenal Cortex Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma Mitotane, Pembrolizumab - Adrenocortical Carcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2023-03-23 | 2025-06-19 |
| Milademetan in Advanced/Metastatic Solid Tumors RAIN-32 - Solid Tumors, Head and Neck Carcinoma | Phase 2 | Terminated | Rain Oncology Inc | 40 | 2021-11-01 | 2024-10-17 |
| A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma EO2401, Nivolumab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 1 / Phase 2 | Terminated | Enterome | 70 | 2020-07-23 | 2026-01-30 |
| Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Laboratory Biomarker Analysis, Nivolumab - Metastatic Carcinoma in the Adrenal Cortex, Recurrent Adrenal Cortex Carcinoma | Phase 2 | Terminated | Northwestern University | 10 | 2016-03-30 | 2019-05-01 |
| IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery IMC-A12, mitotane - Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 20 | 2008-12-01 | 2014-04-29 |
| S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery suramin, therapeutic hydrocortisone - Adrenocortical Carcinoma | Phase 2 | Terminated | SWOG Cancer Research Network | 13 | 1997-03-01 | 2012-10-05 |
| Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Antineoplaston therapy (Atengenal + Astugenal) - Stage IV Adrenocortical Carcinoma | Phase 2 | Terminated | Burzynski Research Institute | 6 | 1996-08-21 | 2018-05-09 |
Adrenocortical Carcinoma (6) · Adenocarcinoma of Lung (1) · Adrenal Cortex Neoplasms (1) · Biliary Tract Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Melanoma (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Paraganglioma (1) · Pheochromocytoma (1) · Sarcoma (1) · Stomach Neoplasms (1) · Testicular Germ Cell Tumor (1) · Uterine Cervical Neoplasms (1)
Adrenal Gland Diseases (7) · Adrenal Gland Neoplasms (7) · Endocrine Gland Neoplasms (7) · Endocrine System Diseases (7) · Neoplasms (7) · Neoplasms by Site (7) · Adenocarcinoma (6) · Adrenal Cortex Neoplasms (6) · Carcinoma (6) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2)
Mitotane (2) · Nivolumab (2) · Dichlorodiphenyldichloroethane (1) · Hydrocortisone (1) · Suramin (1) · antineoplaston A10 (1) · antineoplaston AS 2-1 (1) · cixutumumab (1) · milademetan (1) · pembrolizumab (1)
Burzynski Research Institute (1) · Enterome (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Northwestern University (1) · Rain Oncology Inc (1) · SWOG Cancer Research Network (1)
United States (7) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Spain (1) · Sweden (1)
Benedito Carneiro, MD (1) · Gary Hammer (1) · Jean-Michel Paillarse (1) · Louis E. Schroder, MD (1) · Mouhammed Habra, MD (1) · Stanislaw R. Burzynski, MD, PhD (1)
N01CM00038 (1), N01CM00099 (1), N01CM00100 (1), N01CM62201 (1), N01CM62204 (1), N01CM62205 (1), N01CM62207 (1), P30CA060553 (1), U10CA032102 (1)